POLL: Which 2022 Psoriasis FDA Approval Were You Most Excited About?

The approval expands the IL-23 inhibitor’s indications beyond moderate-to-severe plaque psoriasis to include adults with active psoriatic arthritis.

Updated SKYRIZI labeling allows clinicians to use clinical judgment when determining the need for TB evaluation before treatment.

Experts outline how to recognize undertreated psoriasis, assess incomplete response, and make individualized decisions when escalating therapy.

ORKA-001 achieved PASI 100 in 61% of high-dose patients at week 16 in the phase 2b EVERLAST-B trial of moderate-to-severe psoriasis.

Tina Bhutani-Jacques, MD, explored how disease location, prior treatment response, and patient preference shape topical treatment decisions across 3 plaque psoriasis cases.

Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.